# Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

> **NCT03416153** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 91 (actual)

## Conditions studied

- Oropharynx Cancer

## Interventions

- **DRUG:** Carboplatin
- **RADIATION:** Radiation Therapy
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03416153
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-21
- **Primary completion:** 2023-05-05
- **Final completion:** 2025-05-05
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2025-05-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03416153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03416153, "Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03416153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*